Iovance (IOVA) Q2 Revenue Jumps 93%
Iovance Biotherapeutics (NASDAQ:IOVA), a biotechnology company specializing in cell therapies for solid tumors, reported GAAP earnings on August 7, 2025. The standout news was a 93% year-over-year GAAP revenue growth compared to Q2 2024, driven by its Amtagvi T cell therapy, but both GAAP revenue and earnings fell short of Wall Street expectations. Revenue (GAAP) reached $60.0 million compared to the $67.1 million consensus, while the loss per share of $0.33 (GAAP) was deeper than the projected $0.28 loss. Higher costs, particularly in manufacturing and research and development, contributed to a larger net loss. Despite the revenue miss on a GAAP basis, the company demonstrated ongoing uptake for its core product and maintained its full-year financial guidance, reflecting steady operational progress in a pivotal launch year.
Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report.
Iovance Biotherapeutics develops cell-based immunotherapies, with a focus on tumor-infiltrating lymphocyte (TIL) products for people with advanced cancers. Its core therapy is Amtagvi, a T cell therapy for advanced melanoma that became the first of its kind to earn regulatory approval for solid tumors.
Source Fool.com
